Compugen Announces Second Diagnostic Agreement With Biosite Incorporated
07 Marzo 2007 - 6:00AM
Business Wire
Compugen Ltd. (NASDAQ:CGEN) announced today a second agreement with
Biosite Incorporated for the development and commercialization of
immunoassay diagnostic products. Under the new agreement, in
addition to expanding the number of potential diagnostic biomarkers
available for selection by Biosite, Biosite obtains access to
Compugen�s increasing inventory of immunoassay biomarkers.
Furthermore, the collaboration is expanded to cover cardiovascular,
oncology and additional diagnostic areas. As with the initial
agreement, Compugen will receive milestone payments and royalties
from the sale of any products emerging from the collaboration.
Compugen retains the exclusive right to therapeutic applications of
both the targets and associated antibodies. The collaboration
combines Biosite's expertise in both rapid, high-affinity antibody
development and successful commercialization of proprietary testing
platforms for single and multiple biomarker assays with Compugen's
unique discovery capabilities based on its comprehensive predictive
analysis of the human proteome and related discovery engines.
�Targeting our goal of becoming the world leader in the discovery
and licensing of product candidates to the drug and diagnostic
industry, we must not only enter into new collaborations, but also
build on and strengthen our existing ones,� said Alex Kotzer,
President and Chief Executive Officer of Compugen. �Therefore, we
are very pleased with this significant expansion of our immunoassay
diagnostic collaboration with Biosite, a leading provider of rapid
diagnostic products and antibody development technologies.� About
Compugen Compugen�s mission is to be the world leader in the
discovery and licensing of product candidates to the drug and
diagnostic industry. The Company�s powerful discovery engines
enable the predictive discovery of numerous potential therapeutics
and diagnostic biomarkers. This capability results from the
Company�s decade-long pioneering efforts in the deeper
understanding of important biological phenomena at the molecular
level through the incorporation of ideas and methods from
mathematics, computer science and physics into biology, chemistry
and medicine. To date, Compugen�s diagnostic and therapeutic
product discovery efforts and its initial discovery engines have
focused mainly within the areas of cancer, immune-related and
cardiovascular diseases. The Company's primary commercialization
pathway for its therapeutic and diagnostic product candidates is to
enter into milestone and revenue sharing out-licensing and joint
development agreements with leading companies. Compugen has
established an agricultural biotechnology affiliate -- Evogene, and
a small-molecule drug discovery affiliate -- Keddem Bioscience. For
additional information, please visit Compugen's corporate Website
at www.cgen.com. This press release may contain "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements include words such as �may�,
�expects�, �anticipates�, �believes�, and �intends�, and describe
opinions about future events. These forward-looking statements
involve known and unknown risks and uncertainties that may cause
the actual results, performance or achievements of Compugen to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with
collaborators; the impact of competitive products and technological
changes; risks relating to the development of new products; and the
ability to implement technological improvements. These and other
factors are identified and more fully explained under the heading
"Risk Factors" in Compugen's annual reports filed with the
Securities and Exchange Commission.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024